Ultragenyx Pharmaceutical(US:RARE) Prnewswire·2026-03-11 13:19Core Viewpoint - Ultragenyx Pharmaceutical Inc is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta, leading to significant stock price declines after study failures were announced [1][2] Summary by Relevant Sections Legal Action - Faruqi & Faruqi, LLP is investigating claims against Ultragenyx and reminds investors of the April 6, 2026 deadline to seek lead plaintiff status in the class action lawsuit [1] - The lawsuit alleges that Ultragenyx executives misrepresented the reliability of information regarding setrusumab's effects and downplayed risks associated with the Phase III Orbit study [1][2] Study Results - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, resulting in a stock price drop of over 25% [1] - On December 29, 2025, Ultragenyx announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, causing a further stock price decline of more than 42% [2] Investor Information - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can choose to serve as lead plaintiff or remain an absent class member [2] - Faruqi & Faruqi encourages individuals with information about Ultragenyx's conduct to come forward, including whistleblowers and former employees [2]